ReviewAnnals of medicine2022
Neurotrophic keratopathy: current challenges and future prospects.
Review in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 76 citations in OpenAlex.
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.International journal of molecular sciences · 2022Trial
- Making Corneal Sensation Testing Accessible: Bench Validation of a Low-Cost Adjustable Monofilament Aesthesiometer.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Comparison of Nerve Growth Factor with Fetal Bovine Serum for Promoting Closure of Defects in Corneal Epithelial Cell Layers.Biomedicines · 2026Article
- Amniotic Membrane-Derived Factors in Immunomodulation and Regenerative Medicine: Current Evidence and Emerging Perspectives in Biomaterials and 3D Bioprinting.Journal of functional biomaterials · 2026Review
- MG53 Coordinates Macrophage Polarization and Neuroimmune Coupling to Promote Corneal Nerve Regeneration via the MPEG1-MVP-STAT6 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Neurotrophic keratopathy patients after minimally invasive corneal neurotization treated with RhNGF eyedrops: a case series.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Endogenous Therapeutic Agents for Acute Corneal and Ocular Surface Injuries.Translational vision science & technology · 2026Review
- Emerging Technologies in Corneal Nerve Evaluation for Dry Eye and Ocular Surface Disease: A Review.Journal of clinical medicine · 2026Review
- [Herpes simplex virus keratitis : S1 guidelines of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].Die Ophthalmologie · 2026Review
- Defining Criteria for Choosing Corneal Neurotization in Neurotrophic Keratopathy: A Systematic Review Along with Practical Advices.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Efficacy of Insulin Eye Drops in the Treatment of Corneal Ulcers in Patients with Facial Nerve Palsy and Lagophthalmos: A Retrospective Case-Control Study.Medicina (Kaunas, Lithuania) · 2025Article
- AQP5 Regulates Corneal Nerve Distribution Through NETRIN-1 and SLIT3.Investigative ophthalmology & visual science · 2025Article
- Transforming corneal alkali burn treatment: unveiling mechanisms and pioneering therapies from bench to bedside.Journal of translational medicine · 2025Review
- Functioning and Safety of the Non-Invasive Corneal Esthesiometer Brill: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2025Article
- Corneal neurotization meets COVID-19: a case report of minimally invasive corneal neurotization complicated by COVID-19-related keratitis.Journal of ophthalmic inflammation and infection · 2025Article
- Oculoplastic Interventions in the Management of Ocular Surface Diseases: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The revolutionary role of placental derivatives in biomedical research.Bioactive materials · 2025Review
- Corneal Sensory Denervation Causes Epithelial Ferroptosis and Delayed Healing in Mice.Investigative ophthalmology & visual science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophic keratopathy (NK), or neurotrophic keratitis, is a degenerative condition that results from decreased innervation to the cornea. The cornea is innervated by the ophthalmic branch of the trigeminal nerve. Neurotrophic keratopathy is most commonly caused by herpes keratitis however, any condition that disrupts the normal corneal innervation can cause NK. Neurotrophic keratopathy is a clinical diagnosis and is classified into three stages based on the disease severity. Stage 1 has mild epithelial defects, such as punctate keratopathy, stage 2 disease has persistent epithelial defects, and stage 3 is defined by the presence of ulcers. Current treatment modalities consist of medical and surgical options. Stage 1 is treated with lubrication through artificial tears, eyelid taping, and punctal plug/cautery. Stage 2 treatment can involve therapeutic contact lenses, topical autologous or allogenic serum, tarsorrhaphy, botulinum toxin injections, and possibly anti-inflammatory medications. Stage 3 disease may require human nerve growth factor, amniotic membrane transplantation, conjunctival flap, or corneal neurotization. New therapies, such as matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline represent exciting future options.KEY MESSAGESNeurotrophic keratopathy is a rare degenerative disease defined by decreased innervation to the cornea that is associated with significant morbidity.Treatment options range from lubrication alone to various medical and surgical treatments.Matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline are exciting novel therapies that will influence how neurotrophic keratopathy is treated in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.